Nicolas U Gerber

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3249457/publications.pdf

Version: 2024-02-01

41	810	623734	526287
papers	citations	14 h-index	27 g-index

42	42	42	1219
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial. Neuro-Oncology, 2022, 24, 127-137.	1.2	9
2	Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastomaâ€"an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlentherapie Und Onkologie, 2022, 198, 282-290.	2.0	4
3	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncology, 2022, 24, 997-1007.	1.2	72
4	Central nervous system tumors in children under 5 years of age: a report on treatment burden, survival and long-term outcomes. Journal of Neuro-Oncology, 2022, 157, 307-317.	2.9	3
5	Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial. European Journal of Cancer, 2022, 164, 30-38.	2.8	3
6	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. Journal of Neuro-Oncology, 2022, 157, 37-48.	2.9	2
7	Educational Attainment and Employment Outcome of Survivors of Pediatric CNS Tumors in Switzerlandâ€"A Report from the Swiss Childhood Cancer Survivor Study. Children, 2022, 9, 411.	1.5	4
8	MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma. Neuro-Oncology, 2022, 24, i113-i113.	1.2	0
9	MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate. Neuro-Oncology, 2022, 24, i114-i115.	1.2	0
10	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. Neuro-Oncology, 2022, 24, i61-i62.	1.2	0
11	NFB-13. Rhabdoid Tumor Predisposition Syndrome (RTPS) â€“ Finding Evidence by systematic Analyses. Neuro-Oncology, 2022, 24, i130-i131.	1.2	0
12	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0
13	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy â€“ Results of the MET-HIT2000-BIS4 trial. Neuro-Oncology, 2022, 24, i104-i104.	1.2	1
14	Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma: A BEACON-Neuroblastoma biomarker study.. Journal of Clinical Oncology, 2022, 40, 10039-10039.	1.6	1
15	Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma. Strahlentherapie Und Onkologie, 2021, 197, 674-682.	2.0	16
16	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€"Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
17	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
18	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discovery, 2021, 11, 2764-2779.	9.4	110

#	Article	IF	Citations
19	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2020, 22, 1006-1017.	1.2	72
20	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. European Journal of Cancer, 2020, 141, 82-91.	2.8	15
21	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma â€“ A Report From the HIT 2000 Trial. Advances in Radiation Oncology, 2020, 5, 1158-1169.	1.2	13
22	A single supratentorial highâ€grade neuroepithelial tumor with two distinct BCOR mutations, exceptionally long complete remission and survival. Pediatric Blood and Cancer, 2020, 67, e28384.	1.5	12
23	Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. European Journal of Cancer, 2020, 135, 89-97.	2.8	13
24	Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. Cancers, 2020, 12, 611.	3.7	23
25	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. Journal of Clinical Oncology, 2020, 38, 2028-2040.	1.6	58
26	Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial.. Journal of Clinical Oncology, 2020, 38, 10501-10501.	1.6	4
27	The first report of pediatric patients with solid tumors treated with venetoclax.. Journal of Clinical Oncology, 2020, 38, 10524-10524.	1.6	3
28	PATH-07. QUALITY ASSURANCE IN CEREBROSPINAL FLUID CYTOLOGY ASSESSMENT FOR MEDULLOBLASTOMA STAGING LEADS TO POTENTIAL IMPROVED RISK-GROUP ASSESSMENT IN THE PROSPECTIVE MULTICENTER HIT-2000 TRIAL. Neuro-Oncology, 2020, 22, iii425-iii426.	1.2	1
29	Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. Blood, 2020, 136, 37-38.	1.4	8
30	Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACON-Neuroblastoma randomized phase 2 trialâ€"A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.. Journal of Clinical Oncology, 2019, 37, 10001-10001.	1.6	3
31	Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. European Journal of Cancer, 2018, 100, 27-34.	2.8	22
32	Management of Primary Tectal Plate Low-Grade Glioma in Pediatric Patients: Results of the Multicenter Treatment Study SIOP-LGG 2004. Neuropediatrics, 2018, 49, 314-323.	0.6	14
33	Management of primary thalamic low-grade glioma in pediatric patients: results of the multicenter treatment studies HIT-LGG 1996 and SIOP-LGG 2004. Neuro-Oncology Practice, 2017, 4, 29-39.	1.6	12
34	Ommaya reservoir â€œoffâ€dutyâ€•causing major lateâ€onset complications in a child with medulloblastoma. Pediatric Blood and Cancer, 2017, 64, e26384.	1.5	1
35	Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK).. Journal of Clinical Oncology, 2016, 34, 10551-10551.	1.6	4
36	Ventricular Catheter Systems with Subcutaneous Reservoirs (Ommaya Reservoirs) in Pediatric Patients with Brain Tumors: Infections and Other Complications. Neuropediatrics, 2015, 46, 401-409.	0.6	17

#	Article	IF	Citations
37	Treatment of Children With Central Nervous System Primitive Neuroectodermal Tumors/Pinealoblastomas in the Prospective Multicentric Trial HIT 2000 Using Hyperfractionated Radiation Therapy Followed by Maintenance Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 863-871.	0.8	39
38	Natural history of a medulloblastoma: 30Âmonths of wait and see in a child with a cerebellar incidentaloma. Child's Nervous System, 2013, 29, 1207-1210.	1.1	3
39	A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma. European Journal of Cancer, 2012, 48, 2028-2036.	2.8	16
40	Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-Oncology, 2011, 13, 669-679.	1.2	149
41	Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006. Journal of Neuro-Oncology, 2011, 102, 459-469.	2.9	22